About Amygdala Neurosciences
Amygdala Neurosciences is a company based in San Francisco (United States) founded in 2015 by Peter Strumph. Amygdala Neurosciences has raised $7.05 million across 6 funding rounds from investors including NIH, HHS and ABMRF/The Foundation for Alcohol Research. Amygdala Neurosciences offers products and services including ALDH2 Inhibitors. Amygdala Neurosciences operates in a competitive market with competitors including Indivior, Ethypharm, Braeburn, Cessation Therapeutics and Aelis Farma, among others.
- Headquarter San Francisco, United States
- Founders Peter Strumph
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Amygdala Neurosciences, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$7.05 M (USD)
in 6 rounds
-
Latest Funding Round
Not available
-
Investors
NIH
& 3 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Amygdala Neurosciences
Amygdala Neurosciences offers a comprehensive portfolio of products and services, including ALDH2 Inhibitors.
Inhibitors aimed at treating substance use disorders by reducing cravings.
People of Amygdala Neurosciences
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Amygdala Neurosciences
Amygdala Neurosciences has successfully raised a total of $7.05M across 6 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Amygdala Neurosciences
Amygdala Neurosciences has secured backing from 4 investors, including institutional investors. Prominent investors backing the company include NIH, HHS and ABMRF/The Foundation for Alcohol Research.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Research on alcohol effects is funded by this foundation.
|
Locked | Locked | Locked | |
|
Drug discovery services are provided to the biopharma sector.
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for Amygdala Neurosciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Amygdala Neurosciences
Investment portfolio details for Amygdala Neurosciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Amygdala Neurosciences
Detailed financials for Amygdala Neurosciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Amygdala Neurosciences Comparisons
Peer comparison for Amygdala Neurosciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Amygdala Neurosciences
Amygdala Neurosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Indivior, Ethypharm, Braeburn, Cessation Therapeutics and Aelis Farma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for opioid addiction treatment are developed and commercialized.
|
|
| Locked | Locked | Locked |
Therapies for pain and addiction treatment are developed.
|
|
| Locked | Locked | Locked |
Long-acting therapies for opioid addiction and chronic pain are developed.
|
|
| Locked | Locked | Locked |
Developer of immunotherapy based vaccines to manage addictions
|
|
| Locked | Locked | Locked |
Developer of small molecule drugs targeting CB1 receptor for CNS diseases
|
Detailed competitors of Amygdala Neurosciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Amygdala Neurosciences
Complete news archive for Amygdala Neurosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Amygdala Neurosciences
Amygdala Neurosciences was founded in 2015.
Amygdala Neurosciences is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Peter Strumph is the current CEO of Amygdala Neurosciences. They have also founded this company.
Amygdala Neurosciences is a funded company, having raised a total of $7.05M across 6 funding rounds to date.
Amygdala Neurosciences was founded in 2015 and is based in San Francisco, United States. Focus is placed on the biotechnology sector, where therapies for substance use disorders are developed. The lead candidate, ANS-6637, functions as an aldehyde dehydrogenase (ALDH2) inhibitor targeting seeking behavior, craving, and relapse. Phase I studies have been completed, with preparations underway for a phase II trial.
Amygdala Neurosciences's top competitors include Indivior, Ethypharm and Aelis Farma.
Amygdala Neurosciences offers ALDH2 Inhibitors.
Amygdala Neurosciences has 4 investors. Key investors include NIH, HHS, ABMRF/The Foundation for Alcohol Research, and National Institute on Alcohol Abuse and Alcoholism.